Medical Device News Magazine

Boston Heart Diagnostics Launches LipoMap

One of the Most Comprehensive Assessments of Lipid Metabolism Available

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Boston Heart Diagnostics is pleased to announce the availability of LipoMap™. This panel of 33 lipid, lipoprotein, and apolipoprotein tests is performed via high-resolution 600 MHz nuclear magnetic resonance (NMR) and is one of the most comprehensive assessments of lipid metabolism commercially available.

Under-treated lipid abnormalities contribute to ongoing artery damage, a very common cause of premature cardiovascular disease (CVD) and sudden death. LipoMap™ supports healthcare providers to reduce risk and improve outcomes for patients by identifying hidden anomalies. Despite continued efforts, CVD remains the leading cause of death within the United States and throughout the world. This innovative tool from Boston Heart supports clinicians’ ongoing mission to reduce this disease.

LipoMap™ uncovers a wide variety of treatable and reversible lipid abnormalities that cause CVD, both in patients treated with statin medications and in those who have normal levels of low-density lipoprotein (LDL) cholesterol. Unmasking these characteristics allows for greater personalization of treatment, such as improved medication regimens and targeted lifestyle intervention. Follow-up LipoMap™ testing empowers doctors and patients to measure improvements resulting from enhanced treatments.

LipoMap™ is available from Boston Heart and can be ordered exclusively by healthcare professionals. Just 1 mL of blood is required as the test sample, and results are reported within a week via a secure portal. The report provides overall treatment recommendations, interpretations, and explanations for each of the 33 lipid, lipoprotein, and apolipoprotein test results. These include basic lipids, direct LDL-C, small-dense LDL-C, apoA-I, ApoA-II, ApoB, and particle concentrations for LDL, IDL, VLDL, HDL and six subspecies of LDL particles. LipoMap™ also provides the concentration of ApoB-100 and triglycerides contained in the LDL, IDL, and VLDL particles, and relevant ratios, including free versus esterified cholesterol in HDL and LDL which are increased in certain treatable conditions.

Healthcare providers can access LipoMap™ by contacting Boston Heart Diagnostics at 877.425.1252 or by emailing customercare@bostonheartdx.com.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”